

เอกสารกำกับยาสำหรับบุคลากรทางการแพทย์ ภาษาอังกฤษ

1. Name of the Medicinal Product

SPEVIGO® 450 mg/ 7.5 ml concentration for solution for infusion

2. Qualitative and quantitative composition

SPEVIGO concentrate for solution for infusion contains 60 mg/ml spesolimab.

3. Pharmaceutical Form

Concentrate for solution for infusion.

Colorless to slightly brownish-yellow, clear to slightly opalescent solution

4. Clinical Particulars

4.1 Therapeutic indication

SPEVIGO is indicated for the treatment of flares in adult patients with generalized pustular psoriasis.

4.2 Posology and method of administration

Treatment with SPEVIGO should be initiated and supervised by physicians experienced in the management of patients with inflammatory skin diseases.

Posology

The recommended dose of SPEVIGO is a single dose of 900 mg (two 450 mg/7.5 ml vials) administered as an intravenous infusion.

If flare symptoms persist, an additional 900 mg dose (two 450 mg/7.5 mL vials) may be administered 1 week after the initial dose.

Paediatric patients

The safety and efficacy of SPEVIGO in children below the age of 18 years have not been established. No data are available.

Geriatric patients

No dose adjustment is required.

There is limited information in patients aged 65 years and older.

Patients with renal and/or hepatic impairment

SPEVIGO has not been studied in these patient populations. These conditions are generally not expected to have any clinically relevant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary.

Method of administration

SPEVIGO must be diluted before use. (see section Handling Instructions)

SPEVIGO is administered as a continuous intravenous infusion through an intravenous line containing a sterile, non-pyrogenic, low protein binding in-line filter (pore size of 0.2 micron) over 90 minutes.

In the event that the infusion is slowed or temporarily stopped, the total infusion time (including stop time) should not exceed 180 minutes (see section 4.4).

INSTRUCTIONS FOR USE / HANDLING

Prior to use, the unopened vial may be kept at room temperature (up to 30°C) for up to 24 hours, if stored in the original package in order to protect from light.

The vial should be visually inspected before use. SPEVIGO is a colourless to slightly brownish-yellow, clear to slightly opalescent solution. If the solution is cloudy, discoloured, or contains large or coloured particulates, the vial should be discarded.

Aseptic technique must be used to prepare the solution for infusion. Draw and discard 15 ml from a 100 ml container of sterile 0.9% sodium chloride solution and replace slowly with 15 ml SPEVIGO (two vials of 450 mg/7.5 mL). Mix gently before use. The diluted SPEVIGO infusion solution should be used immediately.

SPEVIGO must not be mixed with other medicinal products. A pre-existing intravenous line may be used for administration of SPEVIGO. The line must be flushed with sterile 0.9% sodium chloride solution prior to and at the end of infusion. No other infusion should be administered in parallel via the same intravenous access.

SPEVIGO is for single-use only and does not contain preservatives.

Chemical and physical in-use stability of the diluted solution has been demonstrated for 24 hours at 2 - 30°C followed by 3 hours infusion time.

From a microbiological point of view the diluted solution for infusion should be used immediately. If not used immediately, in use storage conditions are the responsibility of the user and would normally not be longer than 24 hours at 2 - 8°C, unless dilution has taken place in controlled and validated aseptic conditions. For the time between preparation and start of administration the solution for infusion should be protected from light following local standard procedures.

No incompatibilities have been observed between SPEVIGO and infusion sets composed of polyvinylchloride (PVC), polyethylene (PE), polypropylene (PP), polybutadiene and polyurethane (PUR), and in-line filter membranes composed of polyethersulfone (PES, neutral and positively charged) and positively charged polyamide (PA).

4.3 Contraindication

Severe or life-threatening hypersensitivity to SPEVIGO or to any of the excipients (see section 4.4)

4.4 Special warning and precautions for use

Traceability

In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded in the patient file.

Infections

SPEVIGO may increase the risk of infections. During the 1-week placebo-controlled period in the Effisayil-1 trial, infections were reported in 17.1% of patients treated with SPEVIGO compared with 5.6% of patients treated with placebo (see section 4.8).

In patients with a chronic infection or a history of recurrent infection, the potential risks and expected clinical benefits of treatment should be considered prior to prescribing SPEVIGO. Treatment with SPEVIGO should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. Patients should be instructed to seek medical advice if signs or symptoms of clinically important infection occur after treatment with SPEVIGO.

Pre-treatment evaluation for tuberculosis

Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with SPEVIGO. SPEVIGO should not be administered to patients with active TB infection.

Anti-TB therapy should be considered prior to initiating SPEVIGO in patients with latent TB or a history of TB in whom an adequate course of treatment cannot be confirmed. After SPEVIGO treatment, patients should be monitored for signs and symptoms of active TB.

Hypersensitivity and infusion-related reactions

Hypersensitivity and infusion-related reactions may occur with monoclonal antibodies such as SPEVIGO. Hypersensitivity may include immediate reactions such as anaphylaxis and delayed reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS).

Immediate hypersensitivity reactions, including anaphylactic reactions have been reported in patients treated with SPEVIGO (see section 4.8).

If a patient develops signs of anaphylaxis or other serious hypersensitivity, SPEVIGO should be discontinued immediately and appropriate treatment should be initiated (see section 4.3).

If a patient develops mild or moderate infusion-related reaction, SPEVIGO should be stopped and appropriate medical therapy should be considered (e.g., systemic antihistamines and/or corticosteroids). Upon resolution of the reaction, the infusion may be restarted at a slower infusion rate with gradual increase to complete the infusion (see section 4.2).

Immunisations

No specific studies have been conducted in patients who have recently received live viral or live bacterial vaccines. The interval between live vaccinations and initiation of SPEVIGO therapy should be at least 4 weeks. Live vaccines should not be administered for at least 16 weeks after treatment with SPEVIGO.

Peripheral neuropathy

The potential for peripheral neuropathy with SPEVIGO is unknown. Cases of peripheral neuropathy have been reported in clinical trials with spesolimab. Physicians should be vigilant for symptoms potentially indicative of new-onset peripheral neuropathy.

4.5 Interaction with other medicinal products and other forms of interactions

No interaction studies have been performed.

Live vaccines should not be given concurrently with SPEVIGO (see section 4.4).

4.6 Pregnancy and lactation

Pregnancy

There are limited data from the use of spesolimab in pregnant women. Pre-clinical studies using a surrogate, mouse specific anti-IL36R monoclonal antibody do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is recommended to avoid the use of SPEVIGO in pregnancy, unless the expected clinical benefit clearly outweighs the potential risks.

Lactation

It is unknown whether spesolimab is excreted in human milk. There are no data on the effects on the breastfed infant, or the effects on milk production. Spesolimab is a monoclonal antibody and is expected to be present in human milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to abstain from SPEVIGO therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data available on the effect of spesolimab on human fertility. Pre-clinical studies in mice using a surrogate, mouse specific anti-IL36R monoclonal antibody, do not indicate direct or indirect harmful effects with respect to fertility from antagonism of IL36R.

4.7 Effects on ability to drive and use machine

SPEVIGO has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The safety data provided in the following are based on Effisayil-1, a double-blind, randomised trial comparing a single intravenous 900 mg dose of SPEVIGO (n=35) with placebo (n=18) in patients with generalized pustular psoriasis for up to 12 weeks after treatment and four double-blind, placebo- controlled trials of 254 spesolimab-treated patients who received doses up to 1200 mg intravenous or subcutaneous spesolimab for other diseases as well as open-label extension trials, and post-marketing experience.

The most frequent adverse reactions associated with SPEVIGO are infections.

Tabulated summary of adverse reactions

Table 1 Summary of Adverse Reactions

MedDRA System Organ Class terminology	SPEVIGO adverse reactions
Infections and infestations	Urinary tract infection Upper respiratory tract infection
Immune system disorders	Hypersensitivity*
Skin and subcutaneous tissue disorders	Pruritus
General disorders and administration site conditions	Injection site reactions** Fatigue

*Derived from open-label extension trials and post-marketing experience

**Not reported in Effisayil 1

Description of selected adverse reactions

Infections

During the 1-week placebo-controlled period in Effisayil-1, infections were reported in 17.1% of patients treated with SPEVIGO compared with 5.6% of patients treated with placebo. Serious infection (urinary tract infection) was reported in 1 patient (2.9%) in the SPEVIGO group and no patients in the placebo group. Infections observed in clinical trials with spesolimab were generally mild to moderate with no distinct pattern regarding pathogen or type of infection.

Hypersensitivity

Hypersensitivity comprises immediate systemic hypersensitivity reactions, including anaphylactic reaction. Immediate systemic hypersensitivity reactions have been reported in open-label extension trials and the post-marketing setting.

Injection site reactions

Injection site reactions include injection site erythema, injection site swelling, injection site pain, injection site induration, and injection site warmth. Injection site reactions were typically mild- to-moderate in severity.

4.9 Overdose

There is no clinical experience with overdoses of SPEVIGO.

The highest dose of SPEVIGO administered in clinical trials was 1200 mg. Adverse events observed in subjects receiving single or repeated doses up to 1200 mg were consistent with the known safety profile of SPEVIGO.

In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and symptomatic treatment be instituted as appropriate.

5. Pharmacological Properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group:

Immunosuppressants, Interleukin inhibitors

ATC code:

L04AC22

Mode of Action

Spesolimab is a humanised antagonistic monoclonal immunoglobulin G1 (IgG1) antibody blocking human IL36R signalling. Binding of spesolimab to IL36R prevents the subsequent activation of IL36R by cognate ligands (IL36 α , β and γ) and downstream activation of pro-inflammatory and pro-fibrotic pathways. IL-36R signalling is differentiated from TNF- α , integrin and IL-23 inhibitory pathways by directly and simultaneously blocking both inflammatory and pro-fibrotic pathways. Genetic human studies have established a strong link between IL36R signalling and skin inflammation.

Pharmacodynamics

Following treatment with SPEVIGO in patients with GPP, reduced levels of C-reactive protein (CRP), interleukin (IL)-6, T helper cell (Th1/Th17) mediated cytokines, keratinocyte-mediated inflammation, neutrophilic mediators, and proinflammatory cytokines were observed in serum and skin at week 1 compared to baseline and was associated with a decrease in clinical severity. These reductions in biomarkers became more pronounced at the last measurement at week 8 in Effisayil 1.

Clinical Trials

A randomised, double-blind, placebo-controlled study (Effisayil-1) was conducted to evaluate the clinical efficacy and safety of SPEVIGO in adult patients with flares of Generalized Pustular Psoriasis (GPP), as diagnosed per European Rare And Severe Psoriasis Expert Network (ERASPEN) criteria, regardless of IL36RN mutation status. Patients were randomised if they had a flare of GPP of moderate-to-severe intensity, as defined by a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score (which ranges from 0 [clear] to 4 [severe]) of at least 3 (moderate), presence of fresh pustules (new appearance or worsening of pustules), GPPGA pustulation sub score of at least 2 (mild), and at least 5% of body surface area (BSA)

covered with erythema and the presence of pustules. Patients were required to discontinue systemic and topical therapy for GPP prior to receiving study drug.

The primary endpoint of the study was the proportion of patients with a GPPGA pustulation sub score of 0 (indicating no visible pustules) at Week 1 after treatment. The key secondary endpoint of the study was the proportion of patients with a GPPGA total score of 0 or 1 (clear or almost clear skin) at Week 1. Additional secondary endpoints at Week 4 were the proportion of patients with a 75% reduction in the Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI 75), and patient-reported outcomes including change from baseline in Pain Visual Analog Scale (VAS) score, change from baseline in Psoriasis Symptom Scale (PSS) score, and change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score.

A total of 53 patients were randomised (2:1) to receive a single intravenous dose of 900 mg SPEVIGO (n= 35) or placebo (n=18). Patients in either treatment arm who still experienced flare symptoms at Week 1 were eligible to receive a single intravenous dose of open-label 900 mg SPEVIGO, resulting in 12 patients (34%) in the SPEVIGO arm receiving a second dose of SPEVIGO and 15 patients (83%) in the placebo arm receiving one dose of SPEVIGO on Day 8. In addition, 6 patients (4 SPEVIGO arm; 2 placebo arm) received rescue treatment with a single 900 mg dose of intravenous SPEVIGO for reoccurrence of a flare after Day 8.

The study population consisted of 32% men and 68% women. The mean age was 43 (range: 21 to 69) years; 55% of patients were Asian and 45% were Caucasian. Most patients included in the study had a GPPGA pustulation sub score of 3 (43%) or 4 (36%), and patients had a GPPGA total score of 3 (81%) or 4 (19%). 24.5% of patients had been previously treated with biologic therapy for GPP.

At Week 1, there was a statistically significant difference in the proportion of patients achieving a GPPGA pustulation sub score of 0 (indicating no visible pustules) and GPPGA total score of 0 or 1 (clear or almost clear skin) in the SPEVIGO arm compared with placebo (see Table 2).

Table 2 GPPGA Pustulation Sub Score and GPPGA Total Score at Week 1


	Placebo	SPEVIGO 900mg iv
Number of Patients analysed	18	35
Patients achieving a GPPGA pustulation sub score of 0, n (%)	1 (5.6)	19 (54.3)
Risk difference versus placebo, % (95% CI)	48.7 (21.5, 67.2)	
p-value*	0.0004	
Patients achieving a GPPGA total score of 0 or 1, n (%)	2 (11.1)	15 (42.9)
Risk difference versus placebo, % (95% CI)	31.7 (2.2, 52.7)	
p-value*	0.0118	

GPPGA = Generalized Pustular Psoriasis Physician Global Assessment; iv = intravenous

*One-sided p-value


In patients randomized to SPEVIGO, pustular clearance (GPPGA pustulation sub score of 0) was achieved as early as one day after treatment in 11.4% (4/35) of patients. The effect of up to two doses of SPEVIGO on GPPGA pustulation sub score and GPPGA total score was sustained until Week 12 (see Figures 1 and 2).

Figure 1 Proportion of Patients with a GPPGA Pustulation Sub Score of 0 Over Time



GPPGA = Generalized Pustular Psoriasis Physician Global Assessment

Figure 2 Proportion of Patients with a GPPGA Total Score of 0 or 1 Over Time



GPPGA = Generalized Pustular Psoriasis Physician Global Assessment

The results of the primary and key secondary endpoints were consistent across subgroups including sex, age, race, GPPGA pustulation sub score at baseline, GPPGA total score at baseline, mutation status in IL36RN, and irrespective of any GPP treatment prior to randomization.

At Week 4, 16 patients (46%) randomized to SPEVIGO achieved a GPPASI 75.

In patients randomized to SPEVIGO, improvements in the pain VAS score, PSS score (measuring symptoms of pain, redness, itching, and burning), and FACIT Fatigue score were observed at Week 4 (median change from baseline: -22.45, -2.00 and 3.00, for the pain VAS score, PSS score, and FACIT Fatigue score, respectively).

Immunogenicity

As with all therapeutic proteins, there is the potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.

In patients with GPP treated with Spesolimab in Effisayil-1, anti-drug antibodies (ADA) formed with a median onset of 2.3 weeks. Following administration of i.v. spesolimab 900 mg, 24% of

patients had a maximum ADA titer greater than 4000 and were Neutralising antibody (Nab)-positive by end of the trial (Weeks 12 to 17).

Females appeared to have higher immunogenicity response; the percentage of patients with ADA titer greater than 4000 was 30% in females, and 12% in males, respectively.

In some patients with ADA titer values greater than 4000, plasma spesolimab concentrations were reduced, with no apparent impact on pharmacokinetics at ADA titers below 4000. In the presence of ADA, efficacy was observed upon re-treatment of recurring flares with SPEVIGO in open label extension trial. There was no apparent correlation between the presence of ADA to spesolimab and hypersensitivity reactions.

5.2 Pharmacokinetic properties

A population pharmacokinetic model was developed based on data collected from healthy subjects, patients with GPP and patients with other diseases. After a single i.v. dose of 900 mg, the population PK model-estimated $AUC_{0-\infty}$ (95% CI) and C_{max} (95% CI) in a typical ADA-negative patient with GPP were 4750 (4510, 4970) $\mu\text{g}\cdot\text{day}/\text{mL}$ and 238 (218, 256) $\mu\text{g}/\text{mL}$, respectively.

Distribution

Based on the population pharmacokinetic analysis, the typical volume of distribution at steady state was 6.4 L.

Biotransformation

The metabolic pathway of spesolimab has not been characterized. As a humanized IgG1 monoclonal antibody, spesolimab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.

Elimination

In the linear dose range (0.3 to 20 mg/kg), based on the population PK model, spesolimab clearance (95% CI) in a typical GPP patient without ADA, weighing 70 kg was 0.184 (0.175, 0.194) L/day. The terminal-half-life was 25.5 (24.4, 26.3) days.

Linearity/non-linearity

At low doses, spesolimab exhibited target-mediated drug disposition (TMDD) kinetics after single i.v. dose administration. At doses from 0.01 to 0.3 mg/kg, both clearance (CL) and terminal half-life were dose dependent, and systemic exposure (AUC) increased more than dose proportionally with dose.

The saturation of the nonlinear elimination pathway occurred at about 0.3 mg/kg as spesolimab AUC increased approximately linearly with dose from 0.3 to 20 mg/kg, and CL and terminal half-life were independent of dose.

PK in specific populations

Elderly / Gender / Race

Based on population pharmacokinetic analyses, age, gender and race do not have an effect on the pharmacokinetics of spesolimab.

Hepatic and renal impairment

As a monoclonal antibody, spesolimab is not expected to undergo hepatic or renal elimination. No formal trial of the effect of hepatic or renal impairment on the pharmacokinetics of spesolimab was conducted.

Population PK analysis did not identify mild hepatic impairment or mild or moderate renal impairment as having an influence on the systemic exposure of spesolimab.

Body weight

Spesolimab concentrations were lower in subjects with higher body weight. The impact of body weight on spesolimab plasma concentrations is not expected to be clinically meaningful.

Paediatric population

The pharmacokinetics of spesolimab in paediatric patients has not yet been studied.

Drug-Drug Interactions (studies)

No formal drug interactions studies have been conducted with spesolimab. Population PK analyses indicated that concomitant use of immunosuppressants or oral corticosteroids did not have a direct impact on the pharmacokinetics of spesolimab.

5.3 Preclinical safety data

Toxicology

Pre-clinical data reveal no special hazard for humans.

Repeat dose toxicology studies were conducted in mice using a surrogate, mouse specific anti-IL36R monoclonal antibody by twice weekly intravenous injection for 26 weeks at a dose (50 mg/kg) that was 5 fold higher than the dose that was protective in an experimental mouse colonic inflammation model. No adverse changes in body weight, food consumption or clinical observations were noted at this dose. No adverse effects on clinical pathology parameters including haematology, immunophenotyping, clinical chemistry and histopathology, including lymphoid tissues, have been observed.

The binding specificity of spesolimab to human tissues was evaluated in a tissue cross-reactivity study. No unexpected tissue binding was observed.

Developmental and Reproductive Toxicity

Pre-clinical studies conducted in mice using a surrogate antibody directed towards murine IL36R do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development or fertility, at intravenous doses up to 50 mg/kg twice weekly.

Genotoxicity

Genotoxicity studies have not been conducted with spesolimab.

Carcinogenicity

Carcinogenicity and mutagenicity studies have not been conducted with spesolimab.

6. Pharmaceutical Particulars

6.1 List of excipients

sodium acetate trihydrate, acetic acid, glacial, sucrose, arginine hydrochloride, polysorbate 20, water for injection

This medicine contains 3 mg of polysorbate 20 in each 7.5 ml vial. Polysorbates may cause allergic reactions.

This medicinal—contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium free’.

6.2 Incompatibilities

SPEVIGO must not be mixed with other medicinal products except those mentioned in section 4.2.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not freeze.

Store refrigerated at 2°C - 8°C.

Store in the original package in order to protect from light.

6.5 Nature and contents of container

2 vials containing 7.5 ml of each.

7. Marketing Authorization Holder

Boehringer Ingelheim (Thai) Ltd.

Bangkok, Thailand

8. Marketing Authorization Numbers

1C 19/67 (NBC)

9. Date of First Authorization/Renewal of the Authorization

28 Jun 2024

10. Date of revision of the text

24 Jan 2025